AR and cancer: ProCAIDs study indicate that Capivasertib to chemotherapy did not extend cPFS in mCRPC, but did significantly improve the secondary endpoint of OS (97, 98).In a trial of using samotolisib (PI3K/mTOR dual kinase and DNA-dependent protein kinase inhibitor) combined with ENZ to treat mCRPC patients who experienced cancer progression after treatment with ABI, the combination therapy was tolerable for adverse reactions, significantly improved PFS, and may occur in patients with intact PTEN and no androgen receptor splicing variant 7.